Disclosures for "High Sensitivity for Monogenic Causal Diagnoses in Autism, Including De Novo Variants Representing Novel Disorders, with Trio Whole Genome Sequencing and Data Reanalysis in a Non-Academic Center")
-
Mr. Bar has nothing to disclose.
-
Miss Ebenau has nothing to disclose.
-
The institution of Dr. Mintz has received research support from Aquestive Therapeutics. The institution of Dr. Mintz has received research support from Teva. The institution of Dr. Mintz has received research support from Nuvelution. The institution of Dr. Mintz has received research support from Curemark. The institution of Dr. Mintz has received research support from Otsuka. The institution of Dr. Mintz has received research support from UCB Pharma.
-
Dr. Boles has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for NeuroNeeds . Dr. Boles has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Mitochondrial and Molecular Medicine. Dr. Boles has stock in NeuroNeeds.